Integral Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Integral Diagnostics wird ein jährliches Gewinn- und Umsatzwachstum von 72.4% bzw. 6.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 74.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.5% betragen.

Wichtige Informationen

84.0%

Wachstumsrate der Gewinne

102.8%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	19.3%
Wachstumsrate der Einnahmen	5.9%
Zukünftige Eigenkapitalrendite	8.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17

Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03

Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)

Jan 24

Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?

Jan 14

Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return

Jan 05

Is Integral Diagnostics (ASX:IDX) A Risky Investment?

Dec 26

At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?

Dec 17

What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend

Dec 08

Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture

Nov 29

Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?

Nov 19

Is Integral Diagnostics (ASX:IDX) A Risky Investment?

Sep 20

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Sep 11

Could Integral Diagnostics Limited (ASX:IDX) Have The Makings Of Another Dividend Aristocrat?

Sep 03

Gewinn- und Umsatzwachstumsprognosen

ASX:IDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	534	30	52	77	11
6/30/2025	503	24	40	68	13
6/30/2024	475	-49	25	57	14
12/31/2023	456	-58	20	62	N/A
9/30/2023	449	-16	24	67	N/A
6/30/2023	441	25	27	71	N/A
3/31/2023	418	23	22	58	N/A
12/31/2022	395	21	17	45	N/A
9/30/2022	378	18	13	41	N/A
6/30/2022	361	15	9	37	N/A
3/31/2022	361	18	14	41	N/A
12/31/2021	360	22	18	44	N/A
9/30/2021	356	26	34	57	N/A
6/30/2021	351	31	49	70	N/A
3/31/2021	333	32	54	73	N/A
12/31/2020	315	32	59	76	N/A
9/30/2020	295	28	44	65	N/A
6/30/2020	276	23	28	54	N/A
3/31/2020	263	22	19	47	N/A
12/31/2019	250	21	9	39	N/A
9/30/2019	241	21	12	37	N/A
6/30/2019	232	21	15	34	N/A
3/31/2019	222	19	14	30	N/A
12/31/2018	211	17	13	26	N/A
9/30/2018	200	16	14	26	N/A
6/30/2018	189	15	15	27	N/A
3/31/2018	187	15	17	27	N/A
12/31/2017	185	15	19	27	N/A
9/30/2017	182	15	N/A	25	N/A
6/30/2017	180	15	N/A	23	N/A
3/31/2017	177	16	N/A	26	N/A
12/31/2016	175	16	N/A	30	N/A
9/30/2016	171	14	N/A	27	N/A
6/30/2016	168	11	N/A	24	N/A
3/31/2016	165	11	N/A	22	N/A
12/31/2015	162	11	N/A	20	N/A
9/30/2015	157	8	N/A	18	N/A
6/30/2015	151	5	N/A	17	N/A
6/30/2014	4	3	N/A	4	N/A
6/30/2013	3	3	N/A	4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).

Ertrag vs. Markt: IDX wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: IDX wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: IDXDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (4.9% pro Jahr).

Hohe Wachstumseinnahmen: IDXDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IDXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.5 %).

Integral Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 16%

Consensus forecasts updated

Recent updates

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Consensus EPS estimates fall by 12%

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Consensus EPS estimates fall by 11%

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings: EPS misses analyst expectations

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Consensus EPS estimates fall by 16%

Integral Diagnostics Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued after recent price drop

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Independent Non-Executive Director recently bought AU$114k worth of stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to AU$3.65

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Now 21% undervalued after recent price drop

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Now 21% undervalued

Executive Director recently bought AU$70k worth of stock

Consensus forecasts updated

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Integral Diagnostics Limited Announces the Distribution for the Six Months Ended December 31, 2021, Payable on April 4, 2022

Consensus forecasts updated

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS AU$0.16 (vs AU$0.12 in FY 2020)

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About

Executive Director has left the company

Price target raised to AU$4.99

Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend

Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?

First half 2021 earnings released: EPS AU$0.10 (vs AU$0.062 in 1H 2020)

Revenue beats expectations, earnings disappoint